GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED
大成生化科技集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00809)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

STRATEGIC COOPERATION PLAN IN RELATION TO THE ESTABLISHMENT OF A PILOT TESTING PLATFORM AT XINGLONGSHAN PRODUCTION SITE

This announcement is made by Global Bio-chem Technology Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") on a voluntary basis to keep shareholders and potential investors of the Company informed of the latest development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 20 May 2025, the Group participated in the Conference on the Construction of the Synthetic Biology Industry Innovation Development Pilot Zone in Changchun Economic Development Zone (長春經開區合成生物產業創新發展先導區啓動大會) (the "**Conference**") jointly organised by the Changchun Economic Development Zone Administrative Committee* (長春經濟技術開發區管委會) and Changchun Equity Investment Fund Management Company Limited* (長春市股權投資基金管理有限公司) at which Changchun Hongcheng Biotechnology Development Co., Ltd.* (長春鴻成生物化工材料技術開發有限公司) ("**Hongcheng Biotechnology**"), a wholly-owned subsidiary of the Company, entered into a strategic cooperation framework agreement (the "**Strategic Cooperation Framework Agreement**") with Hefei Hechen Bio-tech Company Limited* (合肥和晨生物科技有限公司) ("**Hefei Hechen**"), a company established in the People's Republic of China (the "**PRC**").

PARTICIPATION AT THE CONFERENCE

On 20 May 2025, the Group participated in the Conference at which attendees, including government authorities at provincial and city levels, the Chinese Academy of Sciences, domestic universities, synthetic biology enterprises, investment companies and fund management entities, came together to form strategic cooperation and signed various framework agreements to establish a pioneer zone for innovation and development of synthetic biological industries in Changchun. The primary focus of the Conference was the signing ceremony for the establishment of the Changxing Oasis Sub-fund* (長興綠洲子基金) with the principal amount of RMB50,000,000 funded by its fund partners aiming to focus on the application of synthetic biotechnology in areas such as bio-manufacturing, agricultural technology and green energy, and facilitating the cooperation of large-scale, high-tech and high-growth enterprises in the country through resources integration to help Changchun city build a synthetic biotechnology industry highland in the Northeast China and promote high-quality development of the industry.

As one of the agendas at the Conference, Hongcheng Biotechnology and Hefei Hechen entered into the Strategic Cooperation Framework Agreement, pursuant to which they will leverage their respective advantages in synthetic biology to focus on applications related to the key industries in Jilin Province to support the development of the province's bio-manufacturing industries. In particular, the strategic cooperation aims to combine the Group's experiences in technology upscaling, process optimisation, production workflow design and cost control, etc. with Hefei Hechen's advantages in the field of synthetic biology including its technologies in gene design, strain construction and metabolic pathway optimisation, to jointly promote the industrial application of synthetic biological technology in the amino acid sector, thereby enhancing the market competitiveness of both parties.

Under the current strategic cooperation plan, the Group and Hefei Hechen will utilise the research centres and pilot testing facilities (the "**R&D Facilities**") at the Group's Xinglongshan production site to establish and collaboratively operate a synthetic biology pilot testing platform (合成生物中試平台) (the "**Pilot Testing Platform**"). The R&D Facilities at the Xinglongshan production site consist of factories and plants of approximately 10,000 square metre with four research and development centres for biochemical, bio-fermentation, food and animal protection. It also houses a pilot plant for biological fermentation products equipped with seven pilot testing facilities for bio-chemicals.

Upon the signing of the Strategic Cooperation Framework Agreement, an unveiling ceremony for the Pilot Testing Platform was held successfully at the Conference, signifying the bridging of the "last mile" in the transformation of technological achievements into industrialised outcomes, which supports breakthroughs in industrialisation of biobased chemicals, medical materials and other related fields.

XINGLONGSHAN PRODUCTION SITE

As at the date of this announcement, the operation in the Group's Xinglongshan production site remains suspended.

As disclosed in the Company's annual report for the year ended 31 December 2024, the Group has been exploring opportunities to introduce business alliances or investors in the operations of its production sites and has been proactively working towards resuming production in the Xinglongshan production site to fully utilise its resources and generate synergistic effect. The Board believes that the entering into the Strategic Cooperation Framework Agreement and the collaborative operation of the Pilot Testing Platform with Hefei Hechen contemplated thereunder marks the first step for the gradual resumption of its operation and production at the Xinglongshan production site which would improve the operational efficiency and strengthen the working capital of the Group in the long run.

Moreover, the entering into the Strategic Cooperation Framework provides valuable opportunities for the parties to leverage their respective resources and expertise to create mutual benefits and synergies. Therefore, the Board believes that the strategic cooperation under the Strategic Cooperation Framework Agreement is in line with the Group's long-term development objectives and business development strategy, and is in the interest of the Group and its shareholders as a whole.

INFORMATION OF HEFEI HECHEN

Hefei Hechen is a company established in the PRC with limited liability. It principally engages in the integration of synthetic biology and advanced delivery technology, and focuses on developing raw material products such as bio-based chemicals, specialty amino acids and high value-added active ingredients. It also launches application solutions for beauty products and functional food by leveraging the high value-added active ingredients and its advanced delivery technology.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, Hefei Hechen and its respective ultimate beneficial owners(s) are third parties independent of and not connected with the Company and its connected persons. The Strategic Cooperation Framework Agreement and the collaborative operation of the Pilot Testing Platform with Hefei Hechen contemplated thereunder do not constitute any notifiable transaction or connected transaction of the Company under Chapter 14 and Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. The Company will further issue announcement(s) regarding the Strategic Cooperation Framework Agreement as and when appropriate in accordance with the Listing Rules.

By order of the Board
Global Bio-chem Technology Group Company Limited
Wang Cheng
Chairman

Hong Kong, 23 May 2025

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Wang Cheng and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Li Yuewen; and three independent non-executive Directors, namely, Ms. Jiang Fangfang, Mr. Tan Chao and Ms. Xie Liangqiu.

* *For identification purposes only*